Journal of clinical virology plus最新文献

{"title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study","authors":"Giacomo Stroffolini ,&nbsp;Valentina Dodaro ,&nbsp;Amedeo De Nicolò ,&nbsp;Jessica Cusato ,&nbsp;Giovanni Di Perri ,&nbsp;Antonio D'Avolio ,&nbsp;Lucio Boglione","doi":"10.1016/j.jcvp.2023.100174","DOIUrl":"10.1016/j.jcvp.2023.100174","url":null,"abstract":"<div><h3>Background</h3><p>Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity. TAF is available for older patients, with bone or kidney impairment.</p></div><div><h3>Methods</h3><p>The primary objective was the evaluation of renal function modification in patients who are switching from TDF to TAF; secondary objective was the use of urinary concentration of tenofovir (TFV) as early marker of renal function improvement or worsening.</p><p>Retrospective study including all HBV patients treated with TDF or TAF. Two groups were selected: patients who are switched from TDF to TAF and who continued with TDF. Follow-up was six months.</p></div><div><h3>Results</h3><p>42 subjects were included; 17 were in TAF group (40 %) and 25 in TDF group (60 %). In TDF group, no estimated glomerular filtration rate (eGFR) improvement was observed, while in TAF group increased by 9 ml/min (<em>p</em> &lt; 0.001). Urinary TFV levels increased by 3 ng/mL in TDF group and decreased by 4.5 ng/mL in TAF group (<em>p</em> &lt; 0.001). The relationship between the eGFR and urinary TFV resulted in reverse proportionality (R² = -0.740, <em>p</em> = 0.001) between the two variables. In multivariate analysis eGFR (β = 0.880, <em>p</em> = 0.043) and pretreatment wit adefovir dipivoxil (ADV) resulted significantly related to TFV urinary excretion.</p></div><div><h3>Conclusions</h3><p>Switching from TDF to TAF lead to significant improvement in eGFR and lower toxicity (estimated with TFV urinary excretion) at six months of follow-up. ADV pretreatment should be considered as adjunctive risk factor for nephrotoxicity independently from age and eGFR.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 1","pages":"Article 100174"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038023000418/pdfft?md5=c52cdba2fbf3b35be20b088d9cbd2ba2&pid=1-s2.0-S2667038023000418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138614622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal analysis of the impact of rituximab on circulating EBV miRNAs in three paediatric kidney transplant recipients","authors":"Jaythoon Hassan ,&nbsp;Gabriel Gonzalez ,&nbsp;Maria Stack ,&nbsp;Niamh Dolan ,&nbsp;Clodagh Sweeney ,&nbsp;Cillian De Gascun ,&nbsp;Jeff Connell ,&nbsp;Atif Awan ,&nbsp;Michael Riordan","doi":"10.1016/j.jcvp.2023.100171","DOIUrl":"10.1016/j.jcvp.2023.100171","url":null,"abstract":"<div><h3>Background</h3><p>EBV DNA monitoring is currently the main strategy to identify renal transplant recipients potentially at risk of EBV complications. EBV miRNA expression is markedly altered in different disease presentations associated with EBV. We performed a longitudinal assessment of the impact of rituximab on circulating EBV miRNA in 3 paediatric kidney transplant recipients.</p></div><div><h3>Methods</h3><p>Forty-two miRNAs encoded within 2 EBV open reading frames (BART and BHRF) were examined over a 28-month period using miRNA qPCR custom panels. EBV DNA was measured using qPCR and lymphocyte subsets were measured by flow cytometry.</p></div><div><h3>Results</h3><p>Patients were 3 years post kidney transplant and received cycles of rituximab infusions. Treatment with rituximab caused an immediate depletion of the circulating B cells and reduced the expression of the miRNAs and EBV DNA levels. About 4 months post treatment, as the circulating B cells repopulated, EBV miRNAs levels increased. A total of 29 plasma samples were studied and between 4 and 34 EBV miRNAs were detected. A significant correlation was observed between the numbers of EBV miRNAs expressed and the EBV DNA level (<em>r</em> = 0.63, <em>p</em> = 0.001).</p></div><div><h3>Conclusion</h3><p>We provide an in-depth longitudinal assessment of the impact of rituximab on specific circulating EBV miRNA expression in three paediatric kidney transplant recipients. Rituximab treatment resulted in the reduction of EBV miRNA expression and EBV DNA viral loads. Larger studies are required to determine whether EBV miRNA levels could be useful biomarkers to predict transplant recipients at risk of developing post-transplant lymphoproliferative disease.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 1","pages":"Article 100171"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038023000388/pdfft?md5=91e94c5e8731674c172ec77a5515c422&pid=1-s2.0-S2667038023000388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135765647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection","authors":"Shahrzad Shoraka ,&nbsp;Seyed Reza Mohebbi ,&nbsp;Seyed Masoud Hosseini ,&nbsp;Amir Ghaemi ,&nbsp;Mohammad Reza Zali","doi":"10.1016/j.jcvp.2023.100167","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100167","url":null,"abstract":"<div><p>The pandemic of 2019 coronavirus disease (COVID-19) has become a world public health challenge. A new member of Coronaviridae family, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative of COVID-19. Although SARS-CoV-2 infection has a direct impact on the respiratory function, extra-respiratory complications such as liver damage have been reported in some cases. However, the exact mechanisms of liver injury in SARS-CoV-2 infection remain largely unexplored. It has also been suggested that patients with pre-existing liver disease are significantly influenced by COVID-19. Considering the double burden of chronic liver diseases and SARS-CoV-2 on health systems, investigating the interrelationship between COVID-19 and underlying liver disease and providing clear recommendations on treatment are very much needed.</p><p>Viral hepatitis is recognized as one of the substantial risk factors for chronic liver diseases. Hepatitis B virus (HBV) is a main cause of liver failure, cirrhosis and hepatocellular carcinoma (HCC). Since both HBV and SARS-CoV-2 affect liver physiology, investigating the possible interactions and effects of SARS-CoV-2/HBV co-infection is increasingly important. This review highlighted the molecular and clinical consequences of SARS-CoV-2/HBV co-infection.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100167"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral load in symptomatic and asymptomatic patients infected with SARS-CoV-2. What have we learned?","authors":"Marina Mozgovoj ,&nbsp;Merceder Dieder Graham ,&nbsp;Cecilia Ferrufino ,&nbsp;Sofia Blanc ,&nbsp;Adriana Fernandez Souto ,&nbsp;Marcela Pilloff ,&nbsp;Maria Jose Dus Santos","doi":"10.1016/j.jcvp.2023.100166","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100166","url":null,"abstract":"<div><p>Asymptomatic and presymptomatic patients played a critical role in the maintenance and spread of infection during COVID pandemic. However, conflicting views about the infectiousness of asymptomatic patients have been raised.</p><p>Identification of asymptomatic cases relies on SARS-CoV-2 genome detection and, in the absence of common epidemiological variables, quantification of viral load (VL) has been proposed as an estimator for SARS-CoV-2 transmission.</p><p>Comparison of VLs from symptomatic and asymptomatic patients displayed variable results according to the studied population, the experimental design and the sampling, among other variables.</p><p>The aim of this work was to determine VLs in symptomatic and asymptomatic patients at the time of sampling and to retrospectively determine their relationship with severity of disease and other parameters that affected the course of COVID-19, in two towns located in Buenos Aires, Argentina.</p><p>Results from our study showed that VLs from symptomatic and asymptomatic patients were significantly different when analyzed globally. In addition, significant differences were found when VLs from each COVID-19 wave were analyzed. In the first wave VLs from asymptomatic patients (log10 8,21 gc/µl) were significantly higher than in symptomatic ones (log10 6,51 gc/µl) while; in the second wave, VLs from asymptomatic patients resulted significantly lower than in symptomatic patients (log10 4,51 gc/µl and log10 5,23 gc/µl, respectively). In the third wave, no significant differences were observed between VLs from both types of patients.</p><p>Results from this work demonstrated that the screening of both symptomatic and asymptomatic patients was of utmost importance in order to reduce SARS-CoV-2 transmission to communities.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100166"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure factors associated with SARS-CoV-2 seropositivity are not predictive for higher humoral immune responses: A cross-sectional cohort study in the general population","authors":"D.A.T. Hanssen ,&nbsp;D.M.E. Pagen ,&nbsp;J. Penders ,&nbsp;S. Brinkhues ,&nbsp;N.H.T.M. Dukers-Muijrers ,&nbsp;C.J.P.A. Hoebe ,&nbsp;P.H.M. Savelkoul ,&nbsp;I.H.M. van Loo","doi":"10.1016/j.jcvp.2023.100164","DOIUrl":"10.1016/j.jcvp.2023.100164","url":null,"abstract":"<div><h3>Introduction</h3><p>Higher antibody levels, in particular antibodies directed against the receptor-binding domain (RBD) of the spike protein, protect against re-infection with SARS-CoV-2. Quantitative antibody response data provide insight into population immunity and are essential for decision-making on booster-vaccination strategies. We aimed to identify predictors for higher antibody responses such as gender, age, experienced COVID-19-compatible symptoms, disease severity and exposure to pre-determined risk factors associated with SARS-CoV-2 seropositivity.</p></div><div><h3>Materials and methods</h3><p>Quantitative anti-S-RBD responses were analysed in seropositive vaccine-naive individuals (<em>n</em> = 1,857) from a study population of 10,001 adults, including healthcare workers (<em>n</em> = 211) and individuals with a known date of a positive PCR (<em>n</em> = 214). Regression models tested associations between age, gender, the period of symptoms, disease severity, pre-identified exposure factors associated with SARS-CoV-2 seropositivity, and anti-S-RBD responses.</p></div><div><h3>Results</h3><p>Symptoms of more severe disease (fever and/or dyspnoea: OR 2.42 [95%CI 1.76–3.34], and hospital admission: OR 11.41 [95%CI 4.66–27.97]), and a longer interval between COVID-19-compatible symptoms and serum collection (OR 3.17 [95%CI 1.32–7.63]) were predictive for anti-S-RBD levels ≥300 U/mL. Working in healthcare was inversely associated with anti-S-RBD levels ≥300 U/mL (OR 0.51 [95%CI 0.31–0.82]). None of the pre-identified exposure factors associated with SARS-CoV-2 seropositivity could be identified as predictive of higher anti-S-RBD responses.</p></div><div><h3>Conclusion</h3><p>No exposure factors were identified as predictors of higher neutralising antibody responses. Nevertheless, higher neutralising antibody levels in individuals with more severe symptoms suggest better immunological protection against SARS-CoV-2 re-infection. In seroprevalence studies, that mainly include asymptomatic or mildly infected individuals, the determination of quantitative antibody responses may help in the interpretation of population immunity.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100164"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44178072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative evaluation of SARS-CoV-2 serological tests shows significant variability in performance across different years of infection and between the tests","authors":"Dell-Dylan Kenfack ,&nbsp;Georges Nguefack-Tsague ,&nbsp;Veronique B Penlap ,&nbsp;Martin F Maidadi ,&nbsp;Celestin Godwe ,&nbsp;Nico F Njayou ,&nbsp;Jude D Bigoga ,&nbsp;Francine Ntoumi ,&nbsp;Eitel Mpoudi-Ngole ,&nbsp;Marcel Tongo","doi":"10.1016/j.jcvp.2023.100168","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100168","url":null,"abstract":"<div><h3>Introduction</h3><p>While the global COVID-19 pandemic is slowly coming under control, current efforts are focused on understanding the epidemiology of endemic SARS-CoV-2. The tool of choice for doing so remains serological tests that detect SARS-CoV-2 induced antibodies. However, the performance of these tests should be evaluated to ensure they comply with the specific performance criteria desired by each country that they are used in.</p></div><div><h3>Methods</h3><p>Here, we use pre-COVID-19 plasma and plasma from SARS-CoV-2-infected individuals collected in 2020, 2021 and 2022 to evaluate the performance of two commercial Rapid Lateral Flow (RLF) tests (the PANBIO™ COVID-19 IgG/IgM rapid test and the LABNOVATION™ COVID-19 (SARS-CoV-2) IgG/IgM rapid test) and one commercial ELISA test (the PLATELIA™ SARS-CoV-2 total Ab).</p></div><div><h3>Results</h3><p>We find that whereas the specificity of the two RLF tests is ≥ 95%, it was 91% for the ELISA tests. However, at 14 days post-COVID-19 date of diagnosis (DoD), only the ELISA test constantly achieved a sensitivity of ≥80% over all the three years. In addition, the rate of detection of the two RLF tests varied across the years with a sensitivity ranging from &lt;80% in 2021 to &gt;80% in 2022. More importantly the capacity of these two RLF tests to detect IgG antibodies decreased with time. On the contrary, the sensitivity of the ELISA test was still above 80% more than six months post DoD.</p></div><div><h3>Conclusion</h3><p>We recommend that sero-epidemiological surveys focused on testing antibodies should not rely on performances reported by the assay manufacturers. They should include a formal evaluation of the selected assays to ensure its limitations and strengths conform with the data-accuracy requirements of the surveys.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100168"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical performance evaluation of HCV and HIV-1 assays on the fully automated molecular system Alinity m","authors":"Tung Phan ,&nbsp;Zachary Cravener ,&nbsp;Janet Olean ,&nbsp;Melissa McCullough ,&nbsp;Jamie Gribschaw ,&nbsp;Alan Wells","doi":"10.1016/j.jcvp.2023.100169","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100169","url":null,"abstract":"<div><p>The demand for molecular virology testing continues to grow in clinical laboratories worldwide. The Alinity m system is a fully automated, continuous, random-access molecular diagnostic analyzer that was designed to streamline the laboratory workflow. In this study, we assessed the clinical performance characteristics of the Alinity m HCV and HIV-1 assays to detect and quantify these two bloodborne pathogens in 71 serum and plasma specimens. The overall qualitative agreement between the Alinity m and Abbott m2000 was 100 % for HCV and 94.4 % for HIV-1. Our data demonstrated a weak bias across the quantitative range of the Abbott m2000 and Alinity m HCV and HIV-1 assays, indicating a strong correlation on viral loads between them. Taken together, the Alinity m HCV and HIV-1 assays had comparable results to their current predecessors, the Abbott RealTime HCV and HIV-1 assays.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100169"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the clinical performance of BD SARS-CoV-2 flu assay for BD COR™ System","authors":"Elizabeth Lockamy,&nbsp;Rebekah M. Martin,&nbsp;Jordan Ippolito","doi":"10.1016/j.jcvp.2023.100170","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100170","url":null,"abstract":"<div><h3>Background</h3><p>Differentiating between SARS-CoV-2 and Influenza (flu) A and B is often difficult without laboratory testing as the symptomology of these respiratory viral infections overlap.</p></div><div><h3>Objective</h3><p>Evaluate the clinical performance of the BD COR™ System multiplex assay (COR SC2/Flu) to detect the three viral pathogens using single nasopharyngeal (NP) swabs collected from symptomatic and asymptomatic individuals.</p></div><div><h3>Materials and methods</h3><p>Swabs collected from 203 symptomatic and 144 asymptomatic individuals were tested using COR SC2/Flu. Results were compared to those from the BioFire® Respiratory Panel 2.1 (BioFire RP2.1) and positive and negative percent agreements (PPA and NPA, respectively) with 95% confidence intervals were calculated.</p></div><div><h3>Results</h3><p>For asymptomatic individuals (<em>n</em> = 144), PPA between COR SC2/Flu and BioFire RP2.1 was 100% (95% CI: 79.6–100) and NPA was 97.7% (95% CI: 93.4–99.2) for the SARS-CoV-2 target. For symptomatic individuals (<em>n</em> = 203), PPA was 100% (95% CI: 92.9–100) and NPA 99.3% (95% CI: 96.4–99.9) for the SARS-CoV-2 target. PPA was 94.0% (95% CI: 83.8–97.9) and NPA was 98.7% (95% CI: 95.4–99.6) for the flu A target. PPA was 100% (95% CI: 92.9–100) and NPA was 100% (95% CI: 97.6–100) for flu B.</p></div><div><h3>Conclusion</h3><p>The continued development and validation of multiplex assays to detect SARS-CoV-2, flu A, and flu B should remain a crucial component of diagnostics as these viruses will continue to coexist in the post-pandemic environment. COR SC2/Flu assay performance met the predetermined clinical specifications for PPA and NPA for SARS-CoV-2, flu A, and flu B detection, and should help support infection control efforts of those diseases.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100170"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-infectious neurological complications of COVID-19 – A tertiary care center experience","authors":"S.M. Krishna Mohan M ,&nbsp;Asish Vijayaraghavan ,&nbsp;Soumya Sundaram ,&nbsp;Sruthi S. Nair ,&nbsp;Sajith Sukumaran","doi":"10.1016/j.jcvp.2023.100165","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100165","url":null,"abstract":"<div><h3>Background</h3><p>The neurological manifestations of acute SARS-CoV-2 infection are well established, but limited understanding of the post-infectious neurological complications of COVID-19 (PINCC) contributes to significant morbidity and mortality. Hence in this study, we aimed to describe the clinical, radiological, and electrophysiological spectrum and outcome of PINCC from a tertiary referral center.</p></div><div><h3>Methods</h3><p>We identified 18 cases with diverse neurological manifestations following recovery from an acute SARS-CoV-2 infection. The neurological manifestations, magnetic resonance imaging findings of the brain and spinal cord, nerve conduction studies, and the treatment and outcome data were collected from electronic medical records.</p></div><div><h3>Results</h3><p>The mean age of presentation was 47± 18.5 years, and 11 patients (61 %) were male. For 11 (61 %) patients, prior COVID-19 symptoms were minimal or absent. The mean time to onset of neurological manifestations was 3 weeks after COVID-19 infection (range 1–8 weeks). 14 patients (77.8 %) had central nervous system (CNS) manifestations, and 4 (22.2 %) had peripheral nervous system (PNS) manifestations. The CNS manifestations included cerebrovascular events in 7, demyelination in 4, and aseptic meningitis, amnestic mild cognitive impairment, and disseminated tuberculosis in one case each. PNS manifestations were Guillain-Barré syndrome, mononeuritis multiplex, asymmetric polyradiculoneuropathy, and isolated diaphragm palsy in one patient each.</p></div><div><h3>Conclusion</h3><p>Post-infectious neurological complications of COVID-19 can involve both central and peripheral nervous system and is independent of the severity of acute infection.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100165"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50189707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B and C virus knowledge and infections in Enugu State, Nigeria","authors":"Kingsley Andrew Egbe ,&nbsp;Anthony C. Ike ,&nbsp;Friday Egbe ,&nbsp;Nse F. Unam","doi":"10.1016/j.jcvp.2023.100172","DOIUrl":"https://doi.org/10.1016/j.jcvp.2023.100172","url":null,"abstract":"<div><p>Despite tremendous biotechnological and therapeutic advances, hepatitis B virus (HBV) and hepatitis C virus (HCV) still constitute a significant global health challenge. With Nigeria known to be a high HBV and HCV burden country, increasing knowledge about viral hepatitis in rural and urban settings, combined with testing and vaccination for unexposed individuals, could be an effective strategy to eliminate these viruses in Nigeria. Therefore, we undertook this prospective study to determine the level of knowledge and epidemiology of HBV and HCV in selected communities and towns in Enugu North geopolitical zone. In this study, 52.3 % of the participants admitted to having previously heard about hepatitis B and/or C. Also 71.2 % of the research participants had no prior vaccination against HBV. Based on our findings, the prevalence rate of HBV is 2.8 % and that of HCV is 0 %. With only the HBsAg marker detected using the five-panel test kits, five of our fourteen samples are designated as being in the acute phase. Another three had HBsAg and HBeAg present and were therefore classified as being either in the late acute or chronic phase. We also recorded a single case of waned immunity to HBV. Further studies to determine viral DNA levels and other new seromarkers is recommended along with vaccination of unvaccinated individuals.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"3 4","pages":"Article 100172"},"PeriodicalIF":1.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703802300039X/pdfft?md5=9f2213850d86ba7fa1eea662974b0b07&pid=1-s2.0-S266703802300039X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92148962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}